Defining drug response for stratified medicine.

2.50
Hdl Handle:
http://hdl.handle.net/11287/620415
Title:
Defining drug response for stratified medicine.
Authors:
Lonergan, M.; Senn, S. J.; McNamee, C.; Daly, A. K.; Sutton, R.; Hattersley, Andrew T.; Pearson, E.; Pirmohamed, M.
Abstract:
The premise for stratified medicine is that drug efficacy, drug safety, or both, vary between groups of patients, and biomarkers can be used to facilitate more targeted prescribing, with the aim of improving the benefit:risk ratio of treatment. However, many factors can contribute to the variability in response to drug treatment. Inadequate characterisation of the nature and degree of variability can lead to the identification of biomarkers that have limited utility in clinical settings. Here, we discuss the complexities associated with the investigation of variability in drug efficacy and drug safety, and how consideration of these issues a priori, together with standardisation of phenotypes, can increase both the efficiency of stratification procedures and identification of biomarkers with the potential for clinical impact.
Citation:
Defining drug response for stratified medicine. 2017, 22 (1):173-179 Drug Discov. Today
Publisher:
Elsevier
Journal:
Drug discovery today
Issue Date:
Jan-2017
URI:
http://hdl.handle.net/11287/620415
DOI:
10.1016/j.drudis.2016.10.016
PubMed ID:
27818254
Additional Links:
https://linkinghub.elsevier.com/retrieve/pii/S1359-6446(16)30412-3
Type:
Journal Article
Language:
en
ISSN:
1878-5832
Appears in Collections:
Diabetes/Endocrine Services; 2017 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorLonergan, M.en
dc.contributor.authorSenn, S. J.en
dc.contributor.authorMcNamee, C.en
dc.contributor.authorDaly, A. K.en
dc.contributor.authorSutton, R.en
dc.contributor.authorHattersley, Andrew T.en
dc.contributor.authorPearson, E.en
dc.contributor.authorPirmohamed, M.en
dc.date.accessioned2017-10-04T11:59:24Z-
dc.date.available2017-10-04T11:59:24Z-
dc.date.issued2017-01-
dc.identifier.citationDefining drug response for stratified medicine. 2017, 22 (1):173-179 Drug Discov. Todayen
dc.identifier.issn1878-5832-
dc.identifier.pmid27818254-
dc.identifier.doi10.1016/j.drudis.2016.10.016-
dc.identifier.urihttp://hdl.handle.net/11287/620415-
dc.description.abstractThe premise for stratified medicine is that drug efficacy, drug safety, or both, vary between groups of patients, and biomarkers can be used to facilitate more targeted prescribing, with the aim of improving the benefit:risk ratio of treatment. However, many factors can contribute to the variability in response to drug treatment. Inadequate characterisation of the nature and degree of variability can lead to the identification of biomarkers that have limited utility in clinical settings. Here, we discuss the complexities associated with the investigation of variability in drug efficacy and drug safety, and how consideration of these issues a priori, together with standardisation of phenotypes, can increase both the efficiency of stratification procedures and identification of biomarkers with the potential for clinical impact.en
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urlhttps://linkinghub.elsevier.com/retrieve/pii/S1359-6446(16)30412-3en
dc.rightsArchived with thanks to Drug discovery todayen
dc.subjectWessex Classification Subject Headings::Endocrinology::Diabetesen
dc.titleDefining drug response for stratified medicine.en
dc.typeJournal Articleen
dc.identifier.journalDrug discovery todayen
dc.type.versionPublisheden

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.